BiotechTube

XmAb942 + Placebo

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ulcerative Colitis (UC)

Conditions

Ulcerative Colitis (UC)

Trial Timeline

Oct 10, 2024 → Jan 1, 2029

NCT ID
NCT06619990

About XmAb942 + Placebo

XmAb942 + Placebo is a phase 1/2 stage product being developed by Xencor for Ulcerative Colitis (UC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06619990. Target conditions include Ulcerative Colitis (UC).

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06619990Phase 1/2Recruiting

Competing Products

20 competing products in Ulcerative Colitis (UC)

See all competitors
ProductCompanyStageHype Score
Mirikizumab SC + Mirikizumab IV + Placebo SCEli LillyPhase 3
77
MirikizumabEli LillyPhase 2
52
Azathioprine + PlaceboCelltrionApproved
85
CT-P13 SC (Infliximab)CelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
TacrolimusAstellas PharmaPhase 3
77
tacrolimus + PlaceboAstellas PharmaPhase 3
77
Filgotinib MaleateEisaiApproved
85
AJM300 + PlaceboEisaiPhase 3
77
GSK3050002 + PlaceboEisaiPhase 1
33
adalimumab + placeboEisaiPhase 3
77
E6007 + PlaceboEisaiPhase 2
52
KHK4083 + PlaceboKyowa KirinPhase 2
52
KHK4083 + PlaceboKyowa KirinPhase 1
33
Arm1 + Arm 2Zydus LifesciencesPhase 2
52
Mirikizumab + MirikizumabEli LillyPhase 3
77
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SCEli LillyPhase 3
77
LY3471851 + PlaceboEli LillyPhase 2
52
Mirikizumab + PlaceboEli LillyPhase 2
52
LY4268989 + PlaceboEli LillyPhase 2
52

Other Products from Xencor

XmAb23104Phase 2
47
XmAb20717Phase 2
47
Plamotamab + Tafasitamab + LenalidomidePhase 2
47
vudalimab monotherapyPhase 2
47
XmAb5871Phase 2
47